KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.96

Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.

DIAMOND Study Group, Cheng Xu, Xiao-Yu Liang, Xin-Qiong Huang, Feng Jin, Kun-Yu Yang, Guang-Yuan Hu, Xiao-Dong Zhu, Ying Wang, Ying Huang, Ning Zhang, De-Sheng Hu, Ling Guo, Guo-Rong Zou, Xiao-Zhong Chen, Shao-Wen Xiao, Jin-Gao Li, Liang-Fang Shen, Yuan-Yuan Li, Jing Huang, Guo-Xian Long, Ling Li, Luo Huang, Long-Jiang She, Yuan Wu, Wei-Hua Zeng, Meng-Yun Qiang, Wei-Xin Liu, Yong Su, Ling-Long Tang, Fang-Yun Xie, Fei Han, Li-Xia Lu, Yan-Qun Xiang, Yan-Ping Mao, Wen-Fei Li, Xu Liu, Qi Yang, Guan-Qun Zhou, Rui Guo, Pu-Yun Ouyang, Xiao-Hui Wang, Lei Chen, Li-Ting Liu, Li Lin, Ji-Bin Li, Ai-Hua Lin, Hong-Yun Zhao, Shu-Bin Hong, Yu-Sheng Jie, Hui-Ling Huang, Xu-Hua Tang, Yue-Can Zeng, Jing-Ping Yun, Sheng-Bing Zang, Zi-Ming Du, Zu-Lu Ye, Li-Zhi Liu, Li Tian, Hao-Jiang Li, Ying-Lin Peng, Na Liu, Ying-Qin Li, Ye-Lin Liang, Han-Miao Wei, Yu-Pei Chen, Yuan Zhang, Xiao-Jing Du, Jia-Wei Lv, Ying Sun, Jun Ma

JAMA 334(11) 973-983

PMID40839372
PMCIDPMC12371549
DOI10.1001/jama.2025.13205
发表日期2025-08-21
入排依据:主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
摘要

摘要

IMPORTANCE: With the programmed cell death protein 1 (PD-1) blockade toripalimab, omitting highly toxic concurrent cisplatin may be feasible for nasopharyngeal carcinoma (NPC) without compromising survival. OBJECTIVE: To evaluate the efficacy and safety of toripalimab incorporated into induction chemotherapy and radiotherapy, without concurrent cisplatin, for locoregionally advanced NPC. DESIGN, SETTING, AND PARTICIPANTS: Open-label, multicenter, randomized phase 3 clinical trial conducted from August 2021 to July 2022 at 13 hospitals in China, enrolling 532 patients with T4N1M0 or T1-4N2-3M0 NPC; 400 (75.2%) completed the trial per protocol. The final date of follow-up was March 21, 2025. INTERVENTIONS: Patients were randomly assigned to either the standard therapy group (n = 266), receiving toripalimab with gemcitabine-cisplatin induction chemotherapy and concurrent cisplatin-radiotherapy (100 mg/m2 triweekly for 2 cycles), or the concurrent cisplatin-sparing group (n = 266), receiving the same regimen without concurrent cisplatin. The 17 cycles of toripalimab (240 mg triweekly) were distributed across the induction, radiotherapy, and adjuvant phases as 3, 3, and 11 cycles, respectively. MAIN OUTCOMES AND MEASURES: Coprimary end points were failure-free survival (noninferiority margin, 8%) and incidence of all-grade vomiting (superiority design). Secondary end points included overall survival, locoregional recurrence-free survival, distant metastasis-free survival, safety, tumor response, quality of life, and tolerability. RESULTS: In the 532 patients in the intention-to-treat population (median [IQR] age, 47 [39-54] years; 25.2% women), after a median follow-up of 37.0 (range, 4.0-50.0) months, the concurrent cisplatin-sparing group had a 3-year failure-free survival rate of 88.3% vs 87.6% in the standard therapy group, a difference of 0.7% (lower limit of the 1-sided 95% CI, -3.9%; P = .002 for noninferiority; stratified hazard ratio, 0.92 [95% CI, 0.66-1.79]; log-rank P = .73). In the safety analysis, the incidence of all-grade vomiting was significantly lower in the concurrent cisplatin-sparing group vs the standard therapy group (26.2% [68/260] vs 59.8% [156/261]; difference, 33.6% [1-sided 95% CI, 26.9%-∞]; P < .001). Patient-reported quality of life (participation rate, 87.5%) and tolerability (participation rate, 94.7%) were better in the concurrent cisplatin-sparing group, primarily in gastrointestinal, functional, and global health status. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, among patients with locoregionally advanced NPC, toripalimab combination therapy without concurrent cisplatin was a feasible treatment with high efficacy in failure-free survival and low toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04907370.

KM 提取结果

1 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure4 个面板

Figure 2

Figure 2.. Kaplan-Meier Analysis of Survival in the Intention-to-Treat Population Censored observations in the Kaplan-Meier curves are indicated by vertical lines. The log-rank test was performed using a stratified Cox proportional hazards model; trial center and clinical stage were used as stratification factors. Kaplan-Meier analysis of survival in the per-protocol population is shown in eFigure 3 in Supplement 2.

A

Any treatment failure or death (primary outcome)

Figure 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

All-cause mortality

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台
查看结果
C

Locoregional recurrence or death

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
D

Distant metastasis or death

Figure 2 · Panel D

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1.. Flow of Patients in a Trial of Toripalimab Combination Therapy With or Without Concurrent Cisplatin a Randomization was stratified by trial center and clinical stage. b Three of the 15 patients who discontinued from the concurrent cisplatin–sparing group and 1 of the 19 patients who discontinued from the standard therapy group did not receive radiotherapy. c Three of the 19 patients who dropped out from the standard therapy group after the induction phase did not receive toripalimab during the radiotherapy phase, but resumed it in the adjuvant phase and were consequently excluded from the per-protocol population. GP indicates gemcitabine-cisplatin; PD-1, programmed cell death protein 1.
非 KM Figure